Immunobiology of natural killer cells and bone marrow transplantation: Merging of basic and preclinical studies

Immunological Reviews

Volumn 181, Issue , 2001, Pages 279-289

  Murphy, William J ^a,b   Koh, Crystal Y ^b   Raziuddin, Arati ^a   Bennett, Michael ^c   Longo, Dan L ^d  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; DONOR; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOBIOLOGY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

ANIMALS; ANTIGENS, LY; BONE MARROW TRANSPLANTATION; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT REJECTION; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LECTINS, C-TYPE; MEMBRANE GLYCOPROTEINS; MICE; MODELS, BIOLOGICAL; RECEPTORS, IMMUNOLOGIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0034905551     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1810124.x     Document Type: Review

References (71)

1. Peculiar immunobiology of bone marrow allografts. I. Graft rejection by heavily irradiated "responder" mice
2. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by F1 hybrid mice
3. Natural killer cells and bone marrow transplantation
4. Heterogeneity of natural killer cells
5. Biology of natural killer cells
6. Natural killer cells: Their roles in defenses against disease
7. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection
8. Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized
9. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo
10. Production of multiple cytokines by clones of human large granular lymphocytes
11. Human natural killer clones enhance in vitro antibody production by tumour necrosis factor α and γ interferon
12. The functional relevance of NK-cell-mediated upregulation of antigen-specific IgG2a responses
13. Interactions between B lymphocytes and NK cells
14. Cytokine and cytotoxic pathways of NK cell rejection of class I-deficient bone marrow grafts: Influence of mouse colony environment
15. - multipotent marrow progenitor cells
16. Natural killer cell differentiation: Insights from knockout and transgenic mouse models and in vitro systems
17. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18
18. In search of the 'missing self': MHC molecules and NK cell recognition
19. Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts
20. Inhibitory effects of class I molecules on murine NK cells: Speculations on function, specificity and self-tolerance
21. Inhibitory MHC class I receptors on NK and T cells: A standard nomenclature
22. Natural killer cell receptors
23. Divergent functions of lectin-like receptors on NK cells
24. Major histocompatibility complex class I specific receptors on human natural killer and T lymphocytes
25. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer
26. Ly-49 receptor expression and functional analysis in multiple mouse strains
27. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
28. The ILT2(LIR1) and CD94-/NKG2A NK cell receptors respectively recognize HLAG1 and HLA-E
29. Divergent and convergent evolution of NK-cell receptors
30. Identification of the Ly-49L protein: Evidence for activating counterparts in inhibitory Ly49 protein
31. Cloning and characterization of a novel activating Ly49 closely related to Ly49A
32. Differential tyrosine phosphorylation of inhibitory versus activating Ly-49 receptor proteins and their recruitment of SHP-1 phosphatase
33. Structure/function relationship of activating Ly-49D and inhibitory Ly-49G2 NK receptors
34. Immunoreceptor DAPI 2 bearing a tyrosine-based activation motif is involved in activating NK cells
35. DAPI 2 mediated signal transduction in NK cells: A dominant role for the Syk protein tyrosine kinase
36. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells
37. Multifaceted roles of MHC class I and MHC class I-like molecules in T cell activation
38. Costimulation of CD8αβT cells by NKG2D via engagement by MIC induced on virus-infected cells
39. Specificity, tolerance and development regulation of natural killer cells defined by expression of class I-specific Ly49 receptors
40. Acquisition of Ly49 receptor expression by developing natural killer cells
41. The role of Ly49 NK cell subsets in the regulation of murine cytomegalovirus infections
42. + T cells coexpressing the inhibitory major histocompatibility complex class I receptor Ly49G2
43. Cutting edge: The human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis
44. Host MHC class I gene control of NK-cell specificity in the mouse
45. Hematopoietic stem cells are not direct sytotoxic targets of natural killer cells
46. Identification of a subset of murine natural killer cells that mediates rejection of Hh-1d but not Hh-1b bone marrow grafts
47. Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection
48. Ly49I NK cell receptor transgene inhibition of rejection of H2b mouse bone marrow transplants
49. + NK cells are responsible for mediating the rejection of H-2b bone marrow allografts in mice
50. Differential effects of the rejection of bone marrow allografts by the depletion of activating versus inhibiting Ly-49 natural killer cell subsets
51. b bone marrow cell allografts
52. Tolerance and alloreactivity of the Ly49D subset of murine NK cells
53. + NK cells promote hematopoietic growth in H-2d strain mice
54. NK cells in the regulation of hematopoiesis
55. Activated natural killer cells and interleukin-2 promote granulocytic and megakaryocytic reconstitution after syngeneic bone marrow transplantation in mice
56. Hematopoietic growth-promoting effects of natural killer cells in mice in response to in vivo administration of human interleukin-2
57. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: Implications for unrelated bone marrow donor selection
58. - cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers
59. New strategies for preventing graft-versus-host disease
60. A partial conditioning approach to achieve mixed chimerism in the rat: Depletion of host natural killer cells significantly reduces the amount of total body irradiation engraftment
61. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer
62. Activation of B lymphocytes by NK cells
63. The Ly-49 family: Regulation of cytokine production in murine NK cells
64. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: Implications for use LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation
65. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation
66. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation
67. Ctla-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
68. Hybrid resistance and the Ly-49 family of natural killer cell receptors
69. Augmentation of anti-leukemia effects by NK inhibitory receptor blockade
70. Clonal depletion of postthymic T cells: Veto cells kill precursor cytotoxic T lymphocytes
71. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation